Fulgent Genetics, Inc. (NASDAQ:FLGT - Get Free Report) COO Jian Xie sold 689 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $18.26, for a total transaction of $12,581.14. Following the sale, the chief operating officer now directly owns 336,136 shares of the company's stock, valued at $6,137,843.36. The trade was a 0.20 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Fulgent Genetics Trading Up 1.0 %
Shares of Fulgent Genetics stock opened at $18.07 on Thursday. Fulgent Genetics, Inc. has a 12-month low of $16.56 and a 12-month high of $30.68. The firm has a market capitalization of $552.76 million, a price-to-earnings ratio of -3.27 and a beta of 1.51. The firm's 50 day simple moving average is $19.96 and its two-hundred day simple moving average is $21.16.
Wall Street Analyst Weigh In
FLGT has been the subject of a number of analyst reports. StockNews.com cut shares of Fulgent Genetics from a "hold" rating to a "sell" rating in a research report on Wednesday. Piper Sandler decreased their target price on shares of Fulgent Genetics from $26.00 to $22.00 and set a "neutral" rating for the company in a research report on Monday, November 11th.
The latest trend in real estate
From Pacaso | Ad
These vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, they’re being transformed into fully utilized assets. And there’s one company that’s leading the charge – already welcoming over 1,500 happy homeowners into their co-ownership family, earning $100M in gross profits along the way.
Now, for the first time, this innovative company is opening its doors to public investors. Want to learn more about co-ownership and its potential? Check them out – but be aware: their share price is set to change December 5, so you don’t have long to maximize your stake.
Don’t miss your chance to maximize your stake in this co-ownership revolution.
Get Our Latest Stock Analysis on Fulgent Genetics
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the stock. Caxton Associates LP acquired a new position in Fulgent Genetics during the 2nd quarter valued at approximately $492,000. Divisadero Street Capital Management LP increased its stake in Fulgent Genetics by 46.4% during the 2nd quarter. Divisadero Street Capital Management LP now owns 505,212 shares of the company's stock valued at $9,912,000 after purchasing an additional 160,212 shares in the last quarter. Algert Global LLC increased its stake in Fulgent Genetics by 46.1% during the 2nd quarter. Algert Global LLC now owns 81,440 shares of the company's stock valued at $1,598,000 after purchasing an additional 25,680 shares in the last quarter. Acadian Asset Management LLC increased its stake in Fulgent Genetics by 593.5% during the 2nd quarter. Acadian Asset Management LLC now owns 62,724 shares of the company's stock valued at $1,227,000 after purchasing an additional 53,680 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System acquired a new stake in shares of Fulgent Genetics in the first quarter worth $178,000. Institutional investors and hedge funds own 48.06% of the company's stock.
Fulgent Genetics Company Profile
(
Get Free Report)
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
